🧬 Tirzepatide
📑 Contents
What Is Tirzepatide?
Tirzepatide is a first‑in‑class, once‑weekly, subcutaneous dual agonist that activates both the glucose‑dependent insulinotropic polypeptide (GIP) and glucagon‑like peptide‑1 (GLP‑1) receptors . It was first approved by the FDA in May 2022 for type 2 diabetes under the brand name Mounjaro, and in November 2023 for chronic weight management (obesity/overweight) under the brand name Zepbound . In December 2025, Zepbound received an additional approval for moderate‑to‑severe obstructive sleep apnea (OSA) in adults with obesity .
Tirzepatide is a synthetic peptide with 39 amino acids, engineered with fatty‑acid side‑chains to enable once‑weekly dosing . It represents a significant advance over selective GLP‑1 receptor agonists like semaglutide, leveraging the complementary actions of GIP and GLP‑1 to achieve superior metabolic outcomes .
Mechanism of Action
Tirzepatide acts on two key incretin hormone receptors that regulate appetite, glucose metabolism, and energy balance .
Pharmacological studies demonstrate that tirzepatide mimics the actions of native GIP at the GIP receptor but shows bias at the GLP‑1 receptor . This unique imbalanced mechanism—with greater engagement of the GIP receptor—may account for its superior clinical efficacy compared to selective GLP‑1 agonists .
Approved Indications
| Indication | Brand Name | FDA Approval |
|---|---|---|
| Type 2 Diabetes | Mounjaro | May 2022 |
| Chronic Weight Management (BMI ≥30 or ≥27 with ≥1 weight‑related comorbidity) |
Zepbound | November 2023 |
| Moderate‑to‑Severe Obstructive Sleep Apnea (in adults with obesity) | Zepbound | December 2025 |
All indications require use in combination with a reduced‑calorie diet and increased physical activity . Tirzepatide should not be used with other tirzepatide‑containing products or any GLP‑1 receptor agonist medicines .
Efficacy Data
A 2025 meta‑analysis of 14 RCTs (9,968 patients) confirmed tirzepatide’s superiority over placebo and GLP‑1 agonists across all weight‑loss endpoints .
📊 Key Trial Results
- SURMOUNT‑1 (2022): 72‑week trial in adults with obesity (without diabetes). The 15 mg dose achieved a mean weight loss of 20.9%, with 57% of participants losing ≥20% of their body weight .
- SURMOUNT‑5 (2025, NEJM): Head‑to‑head trial of tirzepatide vs. semaglutide in 751 participants. Tirzepatide achieved 20.2% weight loss vs. 13.7% with semaglutide at 72 weeks (P < 0.001) . Nearly one‑third (32%) of tirzepatide users lost ≥25% of body weight, compared with 16% of semaglutide users .
- Cochrane meta‑analysis (2025): Moderate‑certainty evidence showed tirzepatide resulted in a mean 16.0% greater weight reduction than placebo at 52–72 weeks .
- OSA indication: In clinical trials, tirzepatide significantly reduced apnea‑hypopnea index (AHI) and improved oxygenation in adults with moderate‑to‑severe OSA and obesity .
Tirzepatide vs. Semaglutide
The SURMOUNT‑5 trial provided the first direct comparison between the two leading weight‑loss medications .
| Outcome | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Mean weight loss (72 weeks) | 20.2% | 13.7% |
| Participants losing ≥25% | 32% | 16% |
| Waist circumference reduction | Greater | Less |
| Mechanism | Dual GIP/GLP‑1 | GLP‑1 only |
| Side effects | Similar GI profile | Similar GI profile |
The improved performance is linked to tirzepatide’s dual mechanism of action—adding GIP agonism to GLP‑1 agonism, which together reduce hunger, lower blood‑glucose, and affect fat cell metabolism .
Long‑Term Data: SURMOUNT‑MAINTAIN
The SURMOUNT‑MAINTAIN trial, published in The Lancet (May 2026), evaluated the effects of continuing versus discontinuing tirzepatide after initial weight loss .
- Design: 441 participants with obesity underwent 60‑week open‑label weight loss on tirzepatide, followed by 52‑week double‑blind maintenance period.
- Results (112 weeks): Continuing tirzepatide at maximum tolerated dose (10‑15 mg) maintained 21.9% weight loss, compared to 16.6% with 5 mg and 9.9% with placebo (P < 0.0001) .
- Weight regain: Only 8% of patients in the MTD group regained ≥50% of weight lost, compared with 67% of the placebo group .
- Cardiometabolic benefits: Improvements in BMI, waist circumference, glycemia, blood pressure, and lipid profile were maintained with continued therapy .
These findings underscore the importance of continued therapy for long‑term obesity management .
Dosing & Administration
Tirzepatide is administered as a once‑weekly subcutaneous injection, with a gradual dose escalation schedule .
- Starting dose: 2.5 mg once weekly for 4 weeks (not a maintenance dose) .
- Titration: Increase by 2.5 mg increments after at least 4 weeks on the current dose .
- Maintenance doses: 5 mg, 10 mg, or 15 mg once weekly for weight management .
- OSA indication: Maintenance doses of 10 mg or 15 mg are recommended .
- Maximum dose: 15 mg once weekly .
Available in six strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg per 0.5 mL) in single‑dose pens, single‑patient‑use KwikPens, and single‑dose vials .
Safety & Side Effects
⚠️ Boxed Warning
Tirzepatide carries a boxed warning regarding the risk of thyroid C‑cell tumours, based on rodent studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) .
📋 Common Adverse Events
The most common side effects (≥5%) are gastrointestinal:
- Nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia
- Injection site reactions, fatigue, hypersensitivity reactions
- Belching, hair loss, gastroesophageal reflux disease
📋 Serious Risks
- Severe gastrointestinal reactions: Not recommended in patients with gastroparesis .
- Acute kidney injury: From volume depletion due to GI symptoms .
- Acute gallbladder disease: Including cholecystitis and gallstones .
- Acute pancreatitis: Discontinue if suspected .
- Hypoglycemia: Increased risk with insulin or sulfonylureas .
- Diabetic retinopathy complications: Monitor patients with a history .
- Suicidal behaviour and ideation: Monitor for depression or suicidal thoughts .
- Pulmonary aspiration: During general anaesthesia or deep sedation .
Tirzepatide represents a transformative advance in the treatment of obesity, type 2 diabetes, and OSA. Its dual GIP/GLP‑1 mechanism delivers superior weight loss compared to selective GLP‑1 agonists, with a consistent safety profile and convenient once‑weekly dosing. The SURMOUNT program—including the head‑to‑head SURMOUNT‑5 trial and the long‑term SURMOUNT‑MAINTAIN extension—has established a robust evidence base supporting its efficacy and durability. For patients with obesity or overweight and related comorbidities, tirzepatide offers a potent and well‑tolerated therapeutic option.
❓ FAQs About Tirzepatide
📌 Disclosure & Disclaimer
Disclosure: This article is for educational and informational purposes only. The author has no financial ties to Eli Lilly or any other pharmaceutical company mentioned. References reflect current scientific literature, FDA labeling, and regulatory documents—not endorsements.
Disclaimer: This content does not constitute medical advice, diagnosis, or treatment. Tirzepatide is a prescription medication that should only be used under the supervision of a qualified healthcare provider. Always consult your physician before starting or changing any therapy.
Tirzepatide has redefined what’s possible in obesity and metabolic care. Its dual GIP/GLP‑1 mechanism, backed by a robust clinical trial program, offers patients a highly effective and well‑tolerated option for sustainable weight management and beyond. As the evidence base continues to grow, tirzepatide stands as a benchmark against which future therapies will be measured.
Stay informed. Stay evidence‑based.
The future of obesity medicine is dual‑agonist powered.
✧ Written in service of evidence‑based medicine and patient safety ✧